In order to enhance BioLife's financial position and provide its stockholders with increased liquidity opportunities, we assisted BioLife with a capital restructuring, a $15.4 million public offering of units and the conversion of $14.3 million of secured debt into equity. The completion of this restructuring allowed BioLife to uplist to the Nasdaq Capital Market.